| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-730SS | |||
| Azide and BSA Free | NBP2-80985 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56527SS | |||
| Azide and BSA Free | NBP2-80616 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2688SS | |||
| Azide and BSA Free | NBP2-80873 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-156SS | |||
| Azide and BSA Free | NBP2-80857 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-92384-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22127SS | |||
| Azide and BSA Free | NBP2-80575 | |||
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Action potentials were evoked with depolarizing current pulses. (A) Neuron from colonic specimen of non-treated patient fired 1 action potential in response to a depolarizing current. (A') Intracellular injection of carboxyfluorescein during recording confirmed Dogiel type I, uniaxonal morphology. (A](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0005.jpg "Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Action potentials were evoked with depolarizing current pulses. (A) Neuron from colonic specimen of non-treated patient fired 1 action potential in response to a depolarizing current. (A') Intracellular injection of carboxyfluorescein during recording confirmed Dogiel type I, uniaxonal morphology. (A")
![Immunohistochemistry-Paraffin: nNOS Antibody [NB100-858] - Staining of paraffin embedded Human Cortex. Steamed antigen retrieval with citrate buffer pH 6, AP-staining. Antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NB100-858-img0006.jpg)
![Flow Cytometry: nNOS Antibody [NB100-858] - Flow cytometric analysis of paraformaldehyde fixed Kelly cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (1 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/nNOS-Antibody-Flow-Cytometry-NB100-858-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing membrane, cytoplasmic and nuclear staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a-2d) and 7 (4a-4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a-1d) and 7 (3a-3d) days. Myenteric ganglia and neurons labeled with beta-Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of nNOS neurons (green) can be seen at both Days 3 and 7 after oxaliplatin treatment. Scale bar = 20 um. Image collected and cropped by CiteAb from the following publication (www.journal.frontiersin.org/article/10.3389/fnins.2013.00030/abstract) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0004.jpg)
![Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-858_goat-polyclonal-nnos-antibody-310202416284925.jpg)
![Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-858_goat-polyclonal-nnos-antibody-310202416284920.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha and ER beta Antagonists on NE Regulation of VMN nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS) - Panel 2A,F(5, 12)=12.67,p<.0001 - protein expression. Data depict mean normalized protein optical density (O.D.) values+/-SEMfor groups of rats (n=6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nNOS-Antibody-Western-Blot-NBP1-39681-img0007.jpg "Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha and ER beta Antagonists on NE Regulation of VMN nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS) - Panel 2A,F(5, 12)=12.67,p<.0001 - protein expression. Data depict mean normalized protein optical density (O.D.) values+/-SEMfor groups of rats (n=6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: nNOS Antibody [NBP1-39681] - Analysis of anti-nNOS / NOS1 antibody with human brain, cerebellum at concentration 5 ug/ml.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NBP1-39681-img0004.jpg)
![Western Blot: nNOS Antibody [NBP1-39681]](http://images.novusbio.com/fullsize/nNOS-Antibody-Western-Blot-NBP1-39681-img0006.jpg)
![Immunohistochemistry-Paraffin: nNOS Antibody [NBP1-39681] - Analysis of anti-nNOS / NOS1 antibody with human brain, cortex at concentration 5 ug/ml.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NBP1-39681-img0003.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Laser-Catapult Microdissection of Immunolabeled ventromedial hypothalamic nucleus (VMN) GABA or Nitrergic Neurons: Western Blot Confirmation of Accuracy of Immunocytochemical Identification of Neurotransmitter Phenotype. VMN neurons were identified in situ for glutamate decarboxylase65/67 (GAD65/67)- (top row, Panel 1A) or neuronal nitric oxide (nNOS)-immunoreactivity (-ir) (bottom row, Panel 2A); representative GAD65/67- or nNOS-ir-positive neurons are indicated by blue arrows. Areas shown in Panels 1A & 2A were rephotographed after positioning of a continuous laser track (depicted in green) around a single GAD65/67-ir (Panel 1B, blue arrow) or nNOS-ir neuron (Panel 2B, blue arrow) & subsequent ejection of the encircled cell by laser pulse (Panels 1C & 2C). Note that this microdissection technique causes negligible destruction of surrounding tissue & minimal inclusion of adjacent tissue. Western blot analysis of triplicate cell lysate pools produced from immunolabeled GAD65/67 (Panel 1D) or nNOS (Panel 2D) neurons from Veh/Veh animals showed that these proteins are expressed in VMN neuron samples obtained by combinatory immunocytochemistry/laser-catapult microdissection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-39681_rabbit-nnos-pab-310202416154636.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha & ER beta Antagonists on NE Regulation of VMN GAD & nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS)—Panel 2A, F(5, 12) = 12.67, p < .0001—or glutamate decarboxylase65/67 (GAD)—Panel 2B, F(5, 12) = 7.13, p = .0003—protein expression. Data depict mean normalized protein optical density (O.D.) values ± SEM for groups of rats (n = 6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p < .05; **p < .01; ***p < .001. MPP = 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride; PHTPP = 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol; NE = norepinephrine. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-39681_rabbit-nnos-pab-310202416175279.jpg)
![Western Blot: TRA-1-60 (R) Antibody (TRA-1-60(R)) [NB100-730] - Whole cell protein from human ES cells (lane 1), human NTERA-2 cells (lane 2), mouse embryonic fibroblasts (MEF, lane 3) and mouse V6.5 ES cells (lane 4, NBP1-97433) were separated on a 7.5% gel and transferred to PVDF membrane. The membrane was then incubated with anti-TRA1-60(R) antibody at 2 ug/ml and detected with an anti-mouse IgM secondary antibody using chemiluminescence. Note how this antibody specifically detects the TRA1-60(R) epitope only on human cells.](http://images.novusbio.com/fullsize/TRA-1-60-R-Antibody-TRA-1-60-R-Western-Blot-NB100-730-img0009.jpg "Western Blot: TRA-1-60 (R) Antibody (TRA-1-60(R)) [NB100-730] - Whole cell protein from human ES cells (lane 1), human NTERA-2 cells (lane 2), mouse embryonic fibroblasts (MEF, lane 3) and mouse V6.5 ES cells (lane 4, NBP1-97433) were separated on a 7.5% gel and transferred to PVDF membrane. The membrane was then incubated with anti-TRA1-60(R) antibody at 2 ug/ml and detected with an anti-mouse IgM secondary antibody using chemiluminescence. Note how this antibody specifically detects the TRA1-60(R) epitope only on human cells.")
![Immunocytochemistry/Immunofluorescence: TRA-1-60(R) Antibody (TRA-1-60) [NB100-730] - TRA-1-60(R) was detected in immersion fixed ADLF1 (top panel) and FAB2 (bottom panel) induced pluripotent stem cell lines using Mouse Anti-Human TRA-1-60(R) Neuraminidase Resistant Epitope Monoclonal Antibody (Catalog # NB100-730) at 10 ug/mL for 3 hours at room temperature. Cells were stained using an Anti-Mouse IgG Secondary Antibody (red) and counterstained with DAPI (blue). Specific staining was localized to cell surfaces.](http://images.novusbio.com/fullsize/TRA-1-60-R-Antibody-TRA-1-60-Immunocytochemistry-Immunofluorescence-NB100-730-img0011.jpg)
![Flow Cytometry: TRA-1-60(R) Antibody (TRA-1-60) [NB100-730] - BG01V human embryonic stem cells were stained with Mouse Anti-Human TRA-1-60 Neuraminidase Resistant Epitope Monoclonal Antibody (Catalog # NB100-730, filled histogram) or isotype control antibody followed by Phycoerythrin-conjugated Anti-Mouse IgM Secondary Antibody (Catalog # F0116).](http://images.novusbio.com/fullsize/TRA-1-60-R-Antibody-TRA-1-60-Flow-Cytometry-NB100-730-img0012.jpg)
![Western Blot: TRA-1-60 (R) Antibody (TRA-1-60(R)) [NB100-730] - Analysis of NB100-730 expression in NTERA-2 cl.D1 whole cell lysate.](http://images.novusbio.com/fullsize/TRA-1-60-R-Antibody-TRA-1-60-R-Western-Blot-NB100-730-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: TRA-1-60 (R) Antibody (TRA-1-60(R)) [NB100-730] - Human embryonic stem cells stained with TRA-1-60 antibody (Cat# NB100-730) detected with Alexa Fluor 488 anti-mouse IgM secondary antibody.](http://images.novusbio.com/fullsize/TRA-1-60-R-Antibody-TRA-1-60-R-Immunocytochemistry-Immunofluorescence-NB100-730-img0008.jpg)
![Western Blot: Caspase-8 Antibody (90A992) [NB100-56527] - Western blot analysis of Caspase-8 in Jurkat cells using Caspase-8 antibody at 1 ug/ml. Cells were treated with 2 uM staurosporine for different time periods. Caspase-8 activation is detected in western blots by the presence of Caspase-8 cleavage fragments. The antibody detected both pro (full length) and active (cleaved) Caspase-8, depending on the treatment time points. A basal level of endogenously cleaved Caspase-8 can be see in untreated Jurkat cells. Goat anti-mouse lg HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/Caspase-8-Antibody-90A992-Western-Blot-NB100-56527-img0018.jpg "<b>Biological Strategies Validation. </b>Western Blot: Caspase-8 Antibody (90A992) [NB100-56527] - Western blot analysis of Caspase-8 in Jurkat cells using Caspase-8 antibody at 1 ug/ml. Cells were treated with 2 uM staurosporine for different time periods. Caspase-8 activation is detected in western blots by the presence of Caspase-8 cleavage fragments. The antibody detected both pro (full length) and active (cleaved) Caspase-8, depending on the treatment time points. A basal level of endogenously cleaved Caspase-8 can be see in untreated Jurkat cells. Goat anti-mouse lg HRP secondary antibody and PicoTect ECL substrate solution were used for this test.")
![<b>Biological Strategies Validation. </b>Western Blot: Caspase-8 Antibody (90A992) [NB100-56527] - Caspase-8 expression in 786-O and A-498 cellsClose](http://images.novusbio.com/fullsize/Caspase-8-Antibody-90A992-Western-Blot-NB100-56527-img0022.jpg)
![Immunohistochemistry-Paraffin: Caspase-8 Antibody (90A992) [NB100-56527] - Formalin-fixed, paraffin-embedded human spleen (top) and breast (bottom) stained with Caspase-8 antibody at 4 ug/ml. Localization can be cytoplasmic and nuclear. Cancer/normal adjacent tissue array was used for this test. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/Caspase-8-Antibody-90A992-Immunohistochemistry-Paraffin-NB100-56527-img0014.jpg)
![Flow Cytometry: Caspase-8 Antibody (90A992) [NB100-56527] - Flow cytometric analysis of Caspase-8 in HeLa cells using 0.1 ug of Caspase-8 antibody. Shaded histogram represents cells without antibody; green represents isotype control; red represents Caspase-8 antibody. Goat anti-mouse IgG-FITC secondary antibody was used for this test. IC-Flow (Intracellular Staining Flow Cytometry Kit) was used to fix and prepare the cells for staining.](http://images.novusbio.com/fullsize/Caspase-8-Antibody-90A992-Flow-Cytometry-NB100-56527-img0008.jpg)
![Western Blot: Caspase-8 Antibody (90A992) [NB100-56527] - Analysis using the Biotin conjugate of NB100-56527. Detection of human Caspase-8 using Jurkat lysates with NB100-55786 at 2 ug/ml (lane 1) and 0.5 ug/ml (lane 2) dilution. NB100-55786 only detects 55 kDa Caspase-8 in Jurkat cells.](http://images.novusbio.com/fullsize/Caspase-8-Antibody-90A992-Western-Blot-NB100-56527-img0021.jpg)
![Simple Western: Caspase-8 Antibody (90A992) [NB100-56527] - Simple Western lane view shows a specific band for Caspase 8 in 0.5 mg/ml of Hek293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Caspase-8-Antibody-90A992-Simple-Western-NB100-56527-img0019.jpg)
![Simple Western: Mouse Monoclonal Caspase-8 Antibody (90A992) [NB100-56527] - S2/IAPinh induces activation of the extrinsic apoptosis pathway via degradation of cIAP-1. (A) Schematic diagram of the intrinsic and extrinsic apoptosis pathways: arrows represent stimulation. TNFR, tumor necrosis factor receptor; DR4-5, death receptor 4–5; cIAP-1/2, cellular inhibitor of apoptosis protein-1/2; RIPK1, Receptor-interacting serine/threonine-protein kinase 1. (B) Protein expression of cIAP-1, cIAP-2, and XIAP in HPAC cells treated with vehicle, SW43 (10 µM), IAPinh (10 µM), or S2/IAPinh (10 µM) for 6 h. The precursor and cleaved forms of caspases 3, 8, and 9 were also analyzed for these cells using Wes automated capillary blotting system (Protein Simple). (C) Quantification of protein expression. Relative densitometry of each band normalized to the total protein. Data shown as means ± SEM. **P Sci Rep (2024). Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56527_mouse-monoclonal-caspase-8-antibody-90a992-12220251513481.jpg)
![Simple Western: Mouse Monoclonal Caspase-8 Antibody (90A992) [NB100-56527] - S2/IAPinh induces tumor cell death via activation of the extrinsic apoptosis pathway in vivo. KP2 tumor samples collected from animals at 48 h after the treatment with either vehicle, SW43, IAPinh, or S2/IAPinh, were used for analyses. (A) Representative images of TUNEL labeled apoptosis cells in KP2 tumor samples of each group. Nuclei were stained in blue with Hoechst, TUNEL positive cells are in red. Scale bars are equal to 20 µm. (B) Quantification of TUNEL positive cells per area in each group. Data are shown as means ± SEM; ****P Sci Rep (2024). Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56527_mouse-monoclonal-caspase-8-antibody-90a992-12220251513480.jpg)
![Flow Cytometry: CD9 Antibody (MEM-61) [NB500-327] - Staining of human peripheral blood with anti-CD9 (MEM-61) Alexa Fluor® 647.](http://images.novusbio.com/fullsize/CD9-Antibody-MEM-61-Flow-Cytometry-NB500-327-img0008.jpg "Flow Cytometry: CD9 Antibody (MEM-61) [NB500-327] - Staining of human peripheral blood with anti-CD9 (MEM-61) Alexa Fluor® 647.")
![Flow Cytometry: CD9 Antibody (MEM-61) [NB500-327] - Surface staining of NALM-6 human pre-B cell leukemia cell line Total viable cells were used for analysis.](http://images.novusbio.com/fullsize/CD9-Antibody-MEM-61-Flow-Cytometry-NB500-327-img0001.jpg)
![Flow Cytometry: CD9 Antibody (MEM-61) [NB500-327] - Surface staining (mass cytometry) of PBMC after Ficoll-Paque separation with anti-human CD9 (MEM-61) Dy161.](http://images.novusbio.com/fullsize/CD9-Antibody-MEM-61-Flow-Cytometry-NB500-327-img0002.jpg)
![Flow Cytometry: CD9 Antibody (MEM-61) [NB500-327] - Surface staining of human peripheral blood with anti-CD9 (MEM-61) biotin / streptavidin-APC.](http://images.novusbio.com/fullsize/CD9-Antibody-MEM-61-Flow-Cytometry-NB500-327-img0003.jpg)
![Flow Cytometry: CD9 Antibody (MEM-61) [NB500-327] - Surface staining of human peripheral blood with anti-CD9 (MEM-61) APC-CyTM7.](http://images.novusbio.com/fullsize/CD9-Antibody-MEM-61-Flow-Cytometry-NB500-327-img0004.jpg)
![Flow Cytometry: CD9 Antibody (MEM-61) [NB500-327] - Surface staining of human peripheral blood with anti-CD9 (MEM-61) Pacific BlueTM.](http://images.novusbio.com/fullsize/CD9-Antibody-MEM-61-Flow-Cytometry-NB500-327-img0005.jpg)
![Flow Cytometry: CD9 Antibody (MEM-61) [NB500-327] - Staining of human peripheral blood with anti-CD9 (MEM-61) APC.](http://images.novusbio.com/fullsize/CD9-Antibody-MEM-61-Flow-Cytometry-NB500-327-img0006.jpg)
![Flow Cytometry: CD9 Antibody (MEM-61) [NB500-327] - Staining of human peripheral blood with anti-CD9 (MEM-61) PE.](http://images.novusbio.com/fullsize/CD9-Antibody-MEM-61-Flow-Cytometry-NB500-327-img0007.jpg)
![CyTOF-ready: CD9 Antibody (MEM-61) [NB500-327] - Analysis of CD9 antibody on human tissue. Scale, 50um. Image from verified customer review.](http://images.novusbio.com/fullsize/CD9-Antibody-MEM-61-CyTOF-ready-NB500-327-img0009.jpg)
![Western Blot: NG2/MCSP Antibody (LHM 2) [NB100-2688] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and NG2/MCSP (LHM2) knockout (KO) HeLa cell line. PVDF membrane was probed with 1.0 ug/ml of Mouse Anti-Human NG2/MCSP (LHM2) Polyclonal Antibody (Catalog # NB100-2688) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for NG2/MCSP (LHM2) at approximately 300 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Knockout-Validated-NB100-2688-img0015.jpg "<b>Genetic Strategies Validation. </b>Western Blot: NG2/MCSP Antibody (LHM 2) [NB100-2688] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and NG2/MCSP (LHM2) knockout (KO) HeLa cell line. PVDF membrane was probed with 1.0 ug/ml of Mouse Anti-Human NG2/MCSP (LHM2) Polyclonal Antibody (Catalog # NB100-2688) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for NG2/MCSP (LHM2) at approximately 300 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Western Blot: NG2/MCSP Antibody (LHM 2) [NB100-2688] - Analysis of NG2 expression in HeLa whole cell lysate.](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Western-Blot-NB100-2688-img0006.jpg)
![Immunohistochemistry-Paraffin: NG2/MCSP Antibody (LHM 2) [NB100-2688] - Staining of NG2 in human brain using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Immunohistochemistry-Paraffin-NB100-2688-img0005.jpg)
![Flow Cytometry: NG2/MCSP Antibody (LHM 2) [NB100-2688] - A cell surface stain was performed on SK-MEL-28 cells with NG2/MCSP antibody (LHM 2) NB100-2688AF700 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Flow-Cytometry-NB100-2688-img0014.jpg)
![Flow Cytometry: NG2/MCSP Antibody (LHM 2) [NB100-2688] - Antibody was tested at 1:400 in MCF7 cells using an Alexa Fluor 488 secondary (shown in green) alongside unstained cells (shown in red).](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Flow-Cytometry-NB100-2688-img0004.jpg)
![Flow (Cell Surface): NG2/MCSP Antibody (LHM 2) [NB100-2688] - A cell surface stain was performed on U87MG cells with NG2/MCSP antibody (LHM 2) NB100-2688PCP (blue) and a matched isotype control NBP2-27287PCP (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Peridinin-Chlorophyll-Protein complex.](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Flow-Cell-Surface-NB100-2688-img0009.jpg)
![Flow (Cell Surface): NG2/MCSP Antibody (LHM 2) [NB100-2688] - A cell surface stain was performed on U87MG cells with NG2/MCSP antibody (LHM 2) NB100-2688AF647 (blue) and a matched isotype control NBP2-27287AF647 (orange). Cells were incubated in an antibody dilution of 2 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Flow-Cell-Surface-NB100-2688-img0010.jpg)
![Flow (Cell Surface): NG2/MCSP Antibody (LHM 2) [NB100-2688] - A surface stain was performed on A375 Cells with NG2/MCSP (LHM2) antibody NB100-2688 (blue) and a matched isotype control NBP1-43319 (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Flow-Cell-Surface-NB100-2688-img0013.jpg)
![Dual RNAscope ISH-IHC: MRP1 Antibody (IU2H10) [NB400-156] - Formalin-fixed paraffin-embedded tissue sections of human testis were probed for MRP1 mRNA (ACD RNAScope Probe, catalog # 435591; Fast Red chromogen, ACD catalog # 322360). Adjacent tissue section was processed for immunohistochemistry using mouse monoclonal (Novus Biologicals catalog # NB400-156) at 7ug/mL with overnight incubation at 4 degrees Celsius followed by incubation with anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to Leydig cells and seminiferous tubule cells.](http://images.novusbio.com/fullsize/MRP1-Antibody-IU2H10-Dual-RNAscope-ISH-IHC-NB400-156-img0008.jpg "<b>Orthogonal Strategies Validation. </b>Dual RNAscope ISH-IHC: MRP1 Antibody (IU2H10) [NB400-156] - Formalin-fixed paraffin-embedded tissue sections of human testis were probed for MRP1 mRNA (ACD RNAScope Probe, catalog # 435591; Fast Red chromogen, ACD catalog # 322360). Adjacent tissue section was processed for immunohistochemistry using mouse monoclonal (Novus Biologicals catalog # NB400-156) at 7ug/mL with overnight incubation at 4 degrees Celsius followed by incubation with anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to Leydig cells and seminiferous tubule cells.")
![<b>Orthogonal Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: MRP1 Antibody (IU2H10) [NB400-156] - The MRP-1 antibody was tested in HeLa cells at a 1:50 dilution against Dylight 488 (Green). Alpha tubulin and nuclei were counterstained against Dylight 550 (Red) and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/MRP1-Antibody-IU2H10-Immunocytochemistry-Immunofluorescence-NB400-156-img0007.jpg)
![Western Blot: MRP1 Antibody (IU2H10) [NB400-156] - Vector-transfected HEK293 cells 2: MRP1-transfected cells, prep1 3: MRP1-transfected cells, prep2 (the lower band is a degradation product.)](http://images.novusbio.com/fullsize/MRP1-Antibody-IU2H10-Western-Blot-NB400-156-img0006.jpg)
![Immunohistochemistry-Frozen: CD8 Antibody (YTS105.18) [NB200-578] - CD8 alpha Antibody (YTS105.18) [NB200-578] - Staining of a mouse lymph node cryosection with rat anti-mouse CD19, clone 6D5 green in A and rat anti-mouse CD8, red in B. Merged image in C wih nuclei counterstained blue using DAPI. Low power](http://images.novusbio.com/fullsize/CD8-Antibody-YTS105-18-Immunohistochemistry-Frozen-NB200-578-img0006.jpg "Immunohistochemistry-Frozen: CD8 Antibody (YTS105.18) [NB200-578] - CD8 alpha Antibody (YTS105.18) [NB200-578] - Staining of a mouse lymph node cryosection with rat anti-mouse CD19, clone 6D5 green in A and rat anti-mouse CD8, red in B. Merged image in C wih nuclei counterstained blue using DAPI. Low power")
![Flow Cytometry: CD8 Antibody (YTS105.18) [NB200-578] - Staining of mouse spleen cells.](http://images.novusbio.com/fullsize/CD8-Antibody-YTS105-18-Flow-Cytometry-NB200-578-img0003.jpg)
![Immunohistochemistry-Frozen: CD8 Antibody (YTS105.18) [NB200-578] - CD8 alpha Antibody (YTS105.18) [NB200-578] - Staining of Mouse lymph node cryosection with CD8 Antibody and HRP-conjugated goat anti-rat IgG. Low power magnification.](http://images.novusbio.com/fullsize/CD8-Antibody-YTS105-18-Immunohistochemistry-Frozen-NB200-578-img0005.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 downregulates GLUT1 by promoting its ubiquitination. ((B), (D) and (F) T-47D cells were transfected with NDRG2 small interfering RNA (siRNA) 10, 25 and 100 pmol or control siRNA for 48 hours. Next, cell proteins or mRNA were extracted and analysed by immunoblotting (B). beta-actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-Western-Blot-H00057447-M03-img0013.jpg "<b>Genetic Strategies Validation. </b>Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 downregulates GLUT1 by promoting its ubiquitination. ((B), (D) and (F) T-47D cells were transfected with NDRG2 small interfering RNA (siRNA) 10, 25 and 100 pmol or control siRNA for 48 hours. Next, cell proteins or mRNA were extracted and analysed by immunoblotting (B). beta-actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 interacts with GLUT1. SK-BR-3 cells were fixed and incubated with primary antibodies against N-myc downstream-regulated gene 2 (NDRG2) or glucose transporter 1 (GLUT1) and with fluorescein isothiocyanate or a cyanine 3 secondary antibody. Green fluorescence indicates NDRG2 expression, red fluorescence indicates GLUT1 expression and blue fluorescence indicates nuclear staining. The results of the merged images reveal that NDRG2 and GLUT1 were colocalised in the cytoplasm. Image collected and cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-Immunocytochemistry-Immunofluorescence-H00057447-M03-img0005.jpg)
![Immunohistochemistry: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 is correlated with increased survival and negatively correlated with GLUT1 in breast carcinoma. Kaplan-Meier analysis was carried out according to N-myc downstream-regulated gene 2 (NDRG2) expression levels of disease-free survival. Serial immunostained sections for NDRG2 and glucose transporter 1 (GLUT1) in breast cancer and normal tissues were analysed. Original magnification, 40x (top) and 400x (bottom); scale bars = 50 um. Image collected and cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-Immunohistochemistry-H00057447-M03-img0007.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 is correlated with increased survival and negatively correlated with GLUT1 in breast carcinoma. Kaplan-Meier analysis was carried out according to N-myc downstream-regulated gene 2 (NDRG2) expression levels of disease-free survival. Protein was extracted from matched breast tumour tissue (T) and adjacent normal tissue (N) and subjected to immunoblot analysis to examine NDRG2 and GLUT1 expression. beta-actin served as a loading control. P: patient. Image collected and cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-Western-Blot-H00057447-M03-img0008.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 inhibits cell proliferation and reduces the intracellular glucose levels of breast cancer cells. T-47D, MCF-7, Bcap37, MDA-MB-231 and SK-BR-3 cells were collected for the extraction of proteins and analysed for N-myc downstream-regulated gene 2 (NDRG2) expression by immunoblotting. Image collected and cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-Western-Blot-H00057447-M03-img0009.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 inhibits cell proliferation and reduces the intracellular glucose levels of breast cancer cells. Con siRNA. SK-BR-3 cells were cultured to glucose medium at concentrations of 0, 5, 25, 50 and 100 mM for 24 hours, and then the protein or mRNA was extracted for analysis by immunoblotting (E). beta-actin was used as a loading control. The data presented are means +/- SD; error bars represented SD from 3 replicative wells. *P < 0.05 and **P < 0.01 versus control group. Image collected and cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-Western-Blot-H00057447-M03-img0011.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 inhibits cell proliferation and reduces the intracellular glucose levels of breast cancer cells. SK-BR-3 cells with low NDRG2 expression were infected by an adenovirus carrying NDRG2 (Ad-NDRG2) or negative control LacZ (Ad-LacZ), and T-47D cells with high NDRG2 were transfected with small interfering RNA targeting NDRG2 (NDRG2 siRNA) or negative control siRNA (Con siRNA). Thereafter proteins were extracted from these cells and analysed by immunoblotting. beta-actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-Western-Blot-H00057447-M03-img0010.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 interacts with GLUT1. Immunoprecipitation (IP) assays were performed with whole-cell lysates of SK-BR-3 cells pretreated with protein A-conjugated sepharose beads. Whole-cell lysates were probed for input. The antibodies for immunoprecipitation and Western blot (WB) analyses were carried out as indicated. The locations of various proteins are indicated by arrowheads. IgG, Immunoglobulin G. Image collected and cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-Western-Blot-H00057447-M03-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 decreases the glucose uptake and GLUT1 protein levels in SK-BR-3-based subcutaneously xenograft tumours. The experiments illustrated are described in the Methods section. Intratumoural protein expression was assessed by N-myc downstream-regulated gene 2 (NDRG2) and glucose transporter 1 (GLUT1) IHC staining. Representative images are shown. Original magnification: 400 x; Scale bars = 50 um. Image collected and cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-Immunocytochemistry-Immunofluorescence-H00057447-M03-img0006.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - Analysis of NDRG2 expression in Hela S3 NE.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-Western-Blot-H00057447-M03-img0003.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 downregulates GLUT1 by promoting its ubiquitination. SK-BR-3 cells were infected with an adenovirus carrying N-myc downstream-regulated gene 2 (Ad-NDRG2) at 1, 5 and 10 multiplicity of infection (MOI) or Ad-LacZ for 48 hours. Next, cell proteins or mRNA were extracted and analysed by immunoblotting (A). beta-actin was used as a loading control. WB, Western blot. Image collected and cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-Western-Blot-H00057447-M03-img0012.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 decreases the glucose uptake and GLUT1 protein levels in SK-BR-3-based subcutaneously xenograft tumours. The experiments illustrated are described in the Methods section. Proteins of the xenograft tumours from each group were extracted and analysed by immunoblotting to quantify NDRG2 and GLUT1 protein changes. Image collected and cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-Western-Blot-H00057447-M03-img0015.jpg)
![ELISA: NDRG2 Antibody (6A5) [H00057447-M03] - Detection limit for recombinant GST tagged NDRG2 is approximately 0.03ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/NDRG2-Antibody-6A5-ELISA-H00057447-M03-img0002.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 inhibits cell proliferation & reduces intracellular glucose levels of breast cancer cells. (E) & (F) SK-BR-3 cells cultured to glucose medium at concentrations of 0, 5, 25, 50 & 100 mM for 24 hrs, & then the protein or mRNA was extracted for analysis by immunoblotting (E) or real-time PCR (F). beta -actin used as a loading control. The data presented means ± SD; error bars represented SD from 3 replicative wells. *P < 0.05 & **P < 0.01 versus control group. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00057447-m03_mouse-monoclonal-ndrg2-antibody-6a5-310202415304260.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 inhibits cell proliferation & reduces intracellular glucose levels of breast cancer cells. (A) T-47D, MCF-7, Bcap37, MDA-MB-231 & SK-BR-3 cells collected for the extraction of proteins & analysed for N-myc downstream-regulated gene 2 (NDRG2) expression by immunoblotting. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00057447-m03_mouse-monoclonal-ndrg2-antibody-6a5-310202415392511.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 interacts with GLUT1. (A) SK-BR-3 cells were fixed & incubated with primary antibodies against N-myc downstream-regulated gene 2 (NDRG2) or glucose transporter 1 (GLUT1) & with fluorescein isothiocyanate or a cyanine 3 secondary antibody. Green fluorescence indicates NDRG2 expression, red fluorescence indicates GLUT1 expression & blue fluorescence indicates nuclear staining. The results of the merged images reveal that NDRG2 & GLUT1 were colocalised in the cytoplasm. (B) Immunoprecipitation (IP) assays were performed with whole-cell lysates of SK-BR-3 cells pretreated with protein A–conjugated sepharose beads. Whole-cell lysates were probed for input. The antibodies for immunoprecipitation & Western blot (WB) analyses were carried out as indicated. The locations of various proteins are indicated by arrowheads. IgG, Immunoglobulin G. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00057447-m03_mouse-monoclonal-ndrg2-antibody-6a5-31020241548223.jpg)
![Immunocytochemistry/ Immunofluorescence: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 decreases the glucose uptake & GLUT1 protein levels in SK-BR-3-based subcutaneously xenograft tumours. The experiments illustrated are described in the Methods section. (A) Tumour growth was assessed every 3 days until day 21 treatment by measuring two perpendicular diameters & calculating the volume in cubic centimetres. Ad-LacZ, adenovirus expressing LacZ; Ad-NDRG2, adenovirus expressing NDRG2; PFU, Plaque-forming units. The data presented are means ± SD; error bars represent SD from 6 mice. *P < 0.05 & **P < 0.01 versus phosphate-buffered saline (PBS) or Ad-LacZ. (B) Tumour cells were dissociated from xenograft tumours & suspended in PBS after the number of cells was counted. Next, the glucose uptake of cells in each group was detected. The data presented are means ± SD of three independent experiments; error bars represent SD from 6 mice. *P < 0.05 & **P < 0.01 versus PBS or Ad-LacZ. (C) Intratumoural protein expression was assessed by N-myc downstream-regulated gene 2 (NDRG2) & glucose transporter 1 (GLUT1) IHC staining. Representative images are shown. Original magnification: 400 x; Scale bars = 50 μm. (D) Proteins of the xenograft tumours from each group were extracted & analysed by immunoblotting to quantify NDRG2 & GLUT1 protein changes. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00057447-m03_mouse-monoclonal-ndrg2-antibody-6a5-310202415482213.jpg)
![Immunohistochemistry: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 is correlated with increased survival & negatively correlated with GLUT1 in breast carcinoma. Kaplan–Meier analysis was carried out according to N-myc downstream-regulated gene 2 (NDRG2) expression levels of disease-free survival (A) & overall survival (B). (C) Serial immunostained sections for NDRG2 & glucose transporter 1 (GLUT1) in breast cancer & normal tissues were analysed. Original magnification, 40× (top) & 400× (bottom); scale bars = 50 μm. (D) Protein was extracted from matched breast tumour tissue (T) & adjacent normal tissue (N) & subjected to immunoblot analysis to examine NDRG2 & GLUT1 expression. beta -actin served as a loading control. P: patient. Relative expression levels of NDRG2 (E) & GLUT1 (F) in human breast cancer & adjacent normal tissue are shown. immunoreactivity score distribution of cancer & adjacent normal tissue were represented with black & brown closed circles, respectively. The horizontal lines presented are means; error bars represented SD from 30 samples. P < 0.01 was considered a statistically significant difference. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00057447-m03_mouse-monoclonal-ndrg2-antibody-6a5-310202415483635.jpg)
![Immunocytochemistry/ Immunofluorescence: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 interacts with GLUT1. (A) SK-BR-3 cells were fixed & incubated with primary antibodies against N-myc downstream-regulated gene 2 (NDRG2) or glucose transporter 1 (GLUT1) & with fluorescein isothiocyanate or a cyanine 3 secondary antibody. Green fluorescence indicates NDRG2 expression, red fluorescence indicates GLUT1 expression & blue fluorescence indicates nuclear staining. The results of the merged images reveal that NDRG2 & GLUT1 were colocalised in the cytoplasm. (B) Immunoprecipitation (IP) assays were performed with whole-cell lysates of SK-BR-3 cells pretreated with protein A–conjugated sepharose beads. Whole-cell lysates were probed for input. The antibodies for immunoprecipitation & Western blot (WB) analyses were carried out as indicated. The locations of various proteins are indicated by arrowheads. IgG, Immunoglobulin G. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00057447-m03_mouse-monoclonal-ndrg2-antibody-6a5-310202415483614.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 downregulates GLUT1 by promoting its ubiquitination. (A), (C) & (E) SK-BR-3 cells were infected with an adenovirus carrying N-myc downstream-regulated gene 2 (Ad-NDRG2) at 1, 5 & 10 multiplicity of infection (MOI) or Ad-LacZ for 48 hours. (B), (D) & (F) T-47D cells were transfected with NDRG2 small interfering RNA (siRNA) 10, 25 & 100 pmol or control siRNA for 48 hours. Next, cell proteins or mRNA were extracted & analysed by immunoblotting (A) & (B) or by real-time PCR (C) to (F). beta -actin was used as a loading control. (C) – (F) The data presented are the means ± SD of three independent experiments; error bars represent SD from 3 replicative wells. *P < 0.05 & **P < 0.01 versus control group. (G) SK-BR-3 cells were infected with 10 MOI Ad-NDRG2 or Ad-LacZ for 48 hours & then treated with 2 μM, 6 μM or 8 μM MG-132 for 4 hours. Next, the protein was extracted & analysed by immunoblotting. (H) Cell fractions were prepared from the SK-BR-3 cells infected with 10 MOI Ad-NDRG2 or Ad-LacZ for 48 hours, & the membrane & cytosolic fractions of endogenous glucose transporter 1 (GLUT1) protein were detected. Tubulin & beta -actin served as loading controls. (I) SK-BR-3 cells were transfected with hemagglutinin (HA)-ubiquitin plasmid for 6 hours & infected with Ad-NDRG2 or Ad-LacZ for another 48 hours. Subsequently, the cell lysates were collected & analysed by immunoprecipitation (IP) & immunoblotting with GLUT1 & HA antibodies. WB, Western blot. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00057447-m03_mouse-monoclonal-ndrg2-antibody-6a5-310202415482275.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 downregulates GLUT1 by promoting its ubiquitination. (A), (C) & (E) SK-BR-3 cells were infected with an adenovirus carrying N-myc downstream-regulated gene 2 (Ad-NDRG2) at 1, 5 & 10 multiplicity of infection (MOI) or Ad-LacZ for 48 hours. (B), (D) & (F) T-47D cells were transfected with NDRG2 small interfering RNA (siRNA) 10, 25 & 100 pmol or control siRNA for 48 hours. Next, cell proteins or mRNA were extracted & analysed by immunoblotting (A) & (B) or by real-time PCR (C) to (F). beta -actin was used as a loading control. (C) – (F) The data presented are the means ± SD of three independent experiments; error bars represent SD from 3 replicative wells. *P < 0.05 & **P < 0.01 versus control group. (G) SK-BR-3 cells were infected with 10 MOI Ad-NDRG2 or Ad-LacZ for 48 hours & then treated with 2 μM, 6 μM or 8 μM MG-132 for 4 hours. Next, the protein was extracted & analysed by immunoblotting. (H) Cell fractions were prepared from the SK-BR-3 cells infected with 10 MOI Ad-NDRG2 or Ad-LacZ for 48 hours, & the membrane & cytosolic fractions of endogenous glucose transporter 1 (GLUT1) protein were detected. Tubulin & beta -actin served as loading controls. (I) SK-BR-3 cells were transfected with hemagglutinin (HA)-ubiquitin plasmid for 6 hours & infected with Ad-NDRG2 or Ad-LacZ for another 48 hours. Subsequently, the cell lysates were collected & analysed by immunoprecipitation (IP) & immunoblotting with GLUT1 & HA antibodies. WB, Western blot. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00057447-m03_mouse-monoclonal-ndrg2-antibody-6a5-310202415482288.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 decreases the glucose uptake & GLUT1 protein levels in SK-BR-3-based subcutaneously xenograft tumours. The experiments illustrated are described in the Methods section. (A) Tumour growth was assessed every 3 days until day 21 treatment by measuring two perpendicular diameters & calculating the volume in cubic centimetres. Ad-LacZ, adenovirus expressing LacZ; Ad-NDRG2, adenovirus expressing NDRG2; PFU, Plaque-forming units. The data presented are means ± SD; error bars represent SD from 6 mice. *P < 0.05 & **P < 0.01 versus phosphate-buffered saline (PBS) or Ad-LacZ. (B) Tumour cells were dissociated from xenograft tumours & suspended in PBS after the number of cells was counted. Next, the glucose uptake of cells in each group was detected. The data presented are means ± SD of three independent experiments; error bars represent SD from 6 mice. *P < 0.05 & **P < 0.01 versus PBS or Ad-LacZ. (C) Intratumoural protein expression was assessed by N-myc downstream-regulated gene 2 (NDRG2) & glucose transporter 1 (GLUT1) IHC staining. Representative images are shown. Original magnification: 400 x; Scale bars = 50 μm. (D) Proteins of the xenograft tumours from each group were extracted & analysed by immunoblotting to quantify NDRG2 & GLUT1 protein changes. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00057447-m03_mouse-monoclonal-ndrg2-antibody-6a5-310202415482240.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 inhibits cell proliferation & reduces intracellular glucose levels of breast cancer cells. (B) SK-BR-3 cells with low NDRG2 expression infected by an adenovirus carrying NDRG2 (Ad-NDRG2) or negative control LacZ (Ad-LacZ), & T-47D cells with high NDRG2 transfected with small interfering RNA targeting NDRG2 (NDRG2 siRNA) or negative control siRNA (Con siRNA). Thereafter proteins extracted from these cells & analysed by immunoblotting. beta -actin used as a loading control. Before being cultured in 25 mM high-glucose (H.G.) or 5.5 mM low-glucose (L.G.) medium, SK-BR-3 cells infected by Ad-NDRG2 (C) & T-47D cells transfected by NDRG2 siRNA (D). Cell proliferation was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay for 1 to 5 days.Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00057447-m03_mouse-monoclonal-ndrg2-antibody-6a5-310202415485122.jpg)
![Western Blot: NDRG2 Antibody (6A5) [H00057447-M03] - NDRG2 is correlated with increased survival & negatively correlated with GLUT1 in breast carcinoma. Kaplan–Meier analysis was carried out according to N-myc downstream-regulated gene 2 (NDRG2) expression levels of disease-free survival (A) & overall survival (B). (C) Serial immunostained sections for NDRG2 & glucose transporter 1 (GLUT1) in breast cancer & normal tissues were analysed. Original magnification, 40× (top) & 400× (bottom); scale bars = 50 μm. (D) Protein was extracted from matched breast tumour tissue (T) & adjacent normal tissue (N) & subjected to immunoblot analysis to examine NDRG2 & GLUT1 expression. beta -actin served as a loading control. P: patient. Relative expression levels of NDRG2 (E) & GLUT1 (F) in human breast cancer & adjacent normal tissue are shown. immunoreactivity score distribution of cancer & adjacent normal tissue were represented with black & brown closed circles, respectively. The horizontal lines presented are means; error bars represented SD from 30 samples. P < 0.01 was considered a statistically significant difference. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00057447-m03_mouse-monoclonal-ndrg2-antibody-6a5-31020241548518.jpg)
![Western Blot: FOXO3 Antibody [NBP2-16521] - FoxO3 expression in nuclear and cytosolic fraction of human breast cancer cell line MDA-MB-231. Image from verified customer review.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NBP2-16521-img0021.jpg "Western Blot: FOXO3 Antibody [NBP2-16521] - FoxO3 expression in nuclear and cytosolic fraction of human breast cancer cell line MDA-MB-231. Image from verified customer review.")
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Mouse duodenum. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0028.jpg)
![<b>Genetic Strategies Validation. </b>Chromatin Immunoprecipitation (ChIP): FOXO3 Antibody [NBP2-16521] - (D) ChIP assay for LMOD1 and EGFR (as a positive control region) in HCASMC chromatin lysates immunoprecipitated with antibodies to FOXO3 or a negative control rabbit IgG. n = 3. (E) Allele specific ChIP (haploChIP) for FOXO3 protein in DNA derived from cultured HCASMC ChIP experiments. DNA from cell line homozygous for the ancestral allele was used as a positive control and arbitrarily set to 1. Values represent mean +/- standard deviation of triplicates. Similar results were observed from n = 4 independent lines for each genotype. (F) Quantitative RT-PCR analysis of LMOD1 in HCASMCs following knock down of endogenous FOXO3 (F) or overexpression of FOXO3 (G). The results were reproduced in n = 3 independent experiments. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pgen.1007755) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Chromatin-Immunoprecipitation-ChIP-NBP2-16521-img0030.jpg)
![Western Blot: FOXO3 Antibody [NBP2-16521] - 50 ug of mouse brain whole cell lysate). Antibody at 1:500.](http://images.novusbio.com/fullsize/FOXO3A-Antibody-Western-Blot-NBP2-16521-img0002.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Huh-7 xenograft, using FOXO3A antibody at 1:500 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/FOXO3A-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0003.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Rat colon. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0024.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Rat brain. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0026.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Mouse brain. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-Negative-NBP2-16521-img0027.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - Jurkat whole cell lysate/extract A. Control with 2 ug of preimmune rabbit IgG B. Immunoprecipitation of FOXO3A protein by 2 ug of FOXO3A antibody 5% SDS-PAGE The immunoprecipitated FOXO3A protein was detected by FOXO3A antibody diluted at 1:1000. EasyBlot anti-rabbit IgG was used as a secondary reagent.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunoprecipitation-NBP2-16521-img0029.jpg)
![Western Blot: FOXO3 Antibody [NBP2-16521] - LMOD1 expression is mediated by PDGF-BB-FOXO3 signaling cascade.(A) UCSC Browser screenshot of the LMOD1 CAD locus at chromosome 1q32.1 highlighting the candidate causal variant, rs34091558, overlapping ATAC-seq open chromatin & RNA-seq tracks in HCASMCs treated with PDGF-BB (n = 2 biological replicates). Genomic coordinates refer to hg19 assembly. Quantitative RT-PCR (B) & Western blotting (C) data revealing PDGF-BB & phosphorylated-FOXO3 (P-FOXO3) mediated LMOD1 expression. (D) Co-expression microarray analysis performed in a cohort of carotid atherosclerotic plaques (n = 127) indicating that LMOD1 & FOXO3 are positively correlated in arterial tissues. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30444878), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-310202415345315.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - Chemotherapy-induced A2BR expression promotes FOXO3 binding on pluripotency factor genes through decreased H3K27me3 & increased H3K27ac chromatin marks. A & B, MDA-MB-231 NTC or A2BR knockdown subclones were transfected with pLX304 (empty vector, EV) or pLX304 encoding A2BR. Cells were treated with vehicle (V) or 10 nM paclitaxel (P) for 72 h & chromatin immunoprecipitation (ChIP) was performed with antibody against FOXO3. Primers flanking the FOXO3 binding site in the NANOG, SOX2 & KLF4 gene (A) were used for qPCR (B; mean ± SEM; n = 3); **p Sample: Paraffin-embedded human glioblastoma.FOXO3A stained by FOXO3A antibody [C3], C-term (NBP2-16521) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-immunohistochemistry-paraffin-2611202518191319.jpg)
![<b>Genetic Strategies Validation. </b>Non-transfected (-) and transfected (+) C2C12 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with FOXO3A antibody [C3], C-term (NBP2-16521) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-western-blot-2611202518303821.jpg)
![FOXO3A antibody [C3], C-term detects FOXO3A protein at nucleus by immunofluorescent analysis.Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: FOXO3A stained by FOXO3A antibody [C3], C-term (NBP2-16521) diluted at 1:1000.Blue: Hoechst 33342 staining.Scale bar= 10 um.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-immunocytochemistry-immunofluorescence-261120251845408.jpg)
![Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with FOXO3A antibody [C3], C-term (NBP2-16521) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-western-blot-261120251824390.jpg)
![FOXO3A antibody [C3], C-term detects FOXO3A protein at nucleus by immunohistochemical analysis.Sample: Paraffin-embedded mouse testis.FOXO3A stained by FOXO3A antibody [C3], C-term (NBP2-16521) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-immunohistochemistry-paraffin-2611202518441020.jpg)
![Immunohistochemistry-Paraffin: SGLT2/SLC5A2 Antibody [NBP1-92384] - SGLT2/SLC5A2 used at 1:50 on a tenrec kidney. SGLT2/SLC5A2 antibody was used on paraffin-embedded kidney tissue at a concentration of 20ug/mL and left at 4C overnight. HIER was performed in Citrate buffer (pH6) for two hours at 75C. Image from verified customer review.](http://images.novusbio.com/fullsize/SGLT2-SLC5A2-Antibody-Immunohistochemistry-Paraffin-NBP1-92384-img0016.jpg "Immunohistochemistry-Paraffin: SGLT2/SLC5A2 Antibody [NBP1-92384] - SGLT2/SLC5A2 used at 1:50 on a tenrec kidney. SGLT2/SLC5A2 antibody was used on paraffin-embedded kidney tissue at a concentration of 20ug/mL and left at 4C overnight. HIER was performed in Citrate buffer (pH6) for two hours at 75C. Image from verified customer review.")
![Immunohistochemistry-Paraffin: SGLT2/SLC5A2 Antibody [NBP1-92384] - Staining of human lymph node shows no positivity in non-germinal center cells as expected.](http://images.novusbio.com/fullsize/SGLT2-SLC5A2-Antibody-Immunohistochemistry-Paraffin-NBP1-92384-img0014.jpg)
![Immunohistochemistry-Paraffin: SGLT2/SLC5A2 Antibody [NBP1-92384] - Staining of human kidney shows moderate positivity in apical membrane in cells in tubules.](http://images.novusbio.com/fullsize/SGLT2-SLC5A2-Antibody-Immunohistochemistry-Paraffin-NBP1-92384-img0013.jpg)
![Immunohistochemistry-Paraffin: SGLT2/SLC5A2 Antibody [NBP1-92384] - Analysis of SGLT2/SLC5A2 antibody on Canine kidney tissue. HIER was done in pH 6 (Citrate Buffer) for two hours at 75C, and primary antibody was put on at 1:100 overnight at 4C. Image was taken at 40X. Image from verified customer review.](http://images.novusbio.com/fullsize/SGLT2-SLC5A2-Antibody-Immunohistochemistry-Paraffin-NBP1-92384-img0015.jpg)
![Simple Western: AMPK alpha 1 Antibody (2B7) [NBP2-22127] - Simple Western lane view shows a specific band for AMPK Alpha 1 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/AMPK-alpha-1-Antibody-2B7-Simple-Western-NBP2-22127-img0006.jpg "Simple Western: AMPK alpha 1 Antibody (2B7) [NBP2-22127] - Simple Western lane view shows a specific band for AMPK Alpha 1 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Western Blot: AMPK alpha 1 Antibody (2B7) [NBP2-22127] - Western blot analysis using AMPK alpha 1 mouse mAb against Jurkat (1), Hela (2), HepG2 (3), MCF-7 (4), Cos7 (5), NIH/3T3 (6), K562 (7), HEK293 (8), and PC-12 (9) cell lysate.](http://images.novusbio.com/fullsize/AMPK-alpha-1-Antibody-2B7-Western-Blot-NBP2-22127-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: AMPK alpha 1 Antibody (2B7) [NBP2-22127] - Immunofluorescence analysis of NTERA-2 cells using AMPK alpha 1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.](http://images.novusbio.com/fullsize/AMPK-alpha-1-Antibody-2B7-Immunocytochemistry-Immunofluorescence-NBP2-22127-img0004.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: AMPK alpha 1 Antibody (2B7) [NBP2-22127] - Ability to combat ROS varies across cell lines. Western blot analysis showing levels of AMPK and activated AMPK (T172) at 24, 48 and 72 hours following exposure to 0.4 uM GNE-617. Full-length western blots are shown in S2D Fig. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0164166), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/AMPK-alpha-1-Antibody-2B7-Western-Blot-NBP2-22127-img0009.jpg)
![Immunohistochemistry-Paraffin: AMPK alpha 1 Antibody (2B7) [NBP2-22127] - Immunohistochemical analysis of paraffin-embedded ovarian cancer (left) and brain tissues (right) using AMPK alpha 1 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/AMPK-alpha-1-Antibody-2B7-Immunohistochemistry-Paraffin-NBP2-22127-img0005.jpg)
![Flow Cytometry: AMPK alpha 1 Antibody (2B7) [NBP2-22127] - An intracellular stain was performed on NIH3T3 cells with AMPK alpha 1 Antibody (2B7) NBP2-22127 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/AMPK-alpha-1-Antibody-2B7-Flow-Cytometry-NBP2-22127-img0008.jpg)
![Flow Cytometry: AMPK alpha 1 Antibody (2B7) [NBP2-22127] - An intracellular stain was performed on RH-30 cells with AMPK alpha 1 Antibody (2B7) NBP2-22127PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/AMPK-alpha-1-Antibody-2B7-Flow-Cytometry-NBP2-22127-img0007.jpg)
![ELISA: AMPK alpha 1 Antibody (2B7) [NBP2-22127] - Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng).](http://images.novusbio.com/fullsize/AMPK-alpha-1-Antibody-2B7-ELISA-NBP2-22127-img0001.jpg)